Compare MP Materials (MP) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MP Materials vs Moderna, Inc. — how do they compare? MP Materials trades at $54.53 (market cap $9.86B), while Moderna, Inc. trades at $135.99 (market cap $56.02B). The key difference: Moderna, Inc. is far larger — about 5.7× MP Materials's market cap, and Moderna, Inc. is trading nearer its 52-week high, MP Materials nearer its low. Which is the better fit depends on your goals.
| MP | MRNA | |
|---|---|---|
Market Cap | $9.86B | $56.02B |
Sector | Industrials | Health |
52-Week High | $98.65 | $174.38 |
52-Week Low | $38.10 | $22.36 |
Enterprise Value | $9.34B | $52.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MP Materials
MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.
Read more on MP →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
